Concepedia

Publication | Open Access

Tocilizumab in COVID‐19 interstitial pneumonia

18

Citations

15

References

2021

Year

Abstract

Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.

References

YearCitations

Page 1